These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 23407221)
1. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. Jiménez-Fuentes MA; de Souza-Galvao ML; Mila Augé C; Solsona Peiró J; Altet-Gómez MN Int J Tuberc Lung Dis; 2013 Mar; 17(3):326-32. PubMed ID: 23407221 [TBL] [Abstract][Full Text] [Related]
2. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Trajman A; Long R; Zylberberg D; Dion MJ; Al-Otaibi B; Menzies D Int J Tuberc Lung Dis; 2010 May; 14(5):551-9. PubMed ID: 20392347 [TBL] [Abstract][Full Text] [Related]
3. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943 [TBL] [Abstract][Full Text] [Related]
4. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials. Esfahani K; Aspler A; Menzies D; Schwartzman K Int J Tuberc Lung Dis; 2011 Oct; 15(10):1340-6. PubMed ID: 22283892 [TBL] [Abstract][Full Text] [Related]
5. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. Chan PC; Yang CH; Chang LY; Wang KF; Lu BY; Lu CY; Shao PL; Hsueh PR; Fang CT; Huang LM Int J Tuberc Lung Dis; 2012 May; 16(5):633-8. PubMed ID: 22410137 [TBL] [Abstract][Full Text] [Related]
6. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin. Fluegge KR J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583 [TBL] [Abstract][Full Text] [Related]
7. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens. Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733 [TBL] [Abstract][Full Text] [Related]
8. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study. Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. Bright-Thomas R; Nandwani S; Smith J; Morris JA; Ormerod LP Arch Dis Child; 2010 Aug; 95(8):600-2. PubMed ID: 20530147 [TBL] [Abstract][Full Text] [Related]
10. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896 [TBL] [Abstract][Full Text] [Related]
11. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan. Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940 [TBL] [Abstract][Full Text] [Related]
12. Is isoniazid for 6 months more cost-effective than isoniazid for 9 months? Pina JM; Clotet L; Sala MR; Ferrer A; Arias C; Domínguez A Int J Tuberc Lung Dis; 2012 Jun; 16(6):768-73. PubMed ID: 22508169 [TBL] [Abstract][Full Text] [Related]
13. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates. Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035 [TBL] [Abstract][Full Text] [Related]
14. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital. Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study. Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection. Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222 [TBL] [Abstract][Full Text] [Related]
18. [Three-month course of rifampicin and isoniazid for the treatment of latent tuberculous infection]. Salinas C; Pascual Erquicia S; Diez R; Aguirre U; Egurrola M; Altube L; Capelastegui A Med Clin (Barc); 2010 Sep; 135(7):293-9. PubMed ID: 20800162 [TBL] [Abstract][Full Text] [Related]
19. Treatment of Latent Tuberculosis Infection. Haley CA Microbiol Spectr; 2017 Apr; 5(2):. PubMed ID: 28409555 [TBL] [Abstract][Full Text] [Related]
20. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME; Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]